Image Description

INVESTORS
& MEDIA

circle

CYTOKINETICS IN THE NEWS

Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.

Date Title  
November 2017, Rare Disease Report Will Tirasemtiv be Effective in ALS? A Conversation with Fady Malik of Cytokinetics
November 2017, ALS News Today Cytokinetics to Release Phase 3 Tirasemtiv Data Next Month in Support of Likely FDA Filing, VP Says in Interview
September 2017, Life Science Leader Cytokinetics: Keeping Its Sights on Independence
September 2017, Pharma Voice Patient-Centered Trials
August 22, 2017, The Pharma Letter 'Writing on the wall' suggests progress in ALS may be imminent, says Cytokinetics CEO
August 16, 2017, ALS Research Forum Cytokinetics CK-107 Muscles In at Phase 2
July 10, 2017, First World Pharma Spotlight On: Cytokinetics, Astellas muscling up on plans for troponin activators
March 23, 2017, SMA News Today Cytokinetics' CK-2127107 Improves Muscle Function in Mice with SMA, Study Shows
February 3, 2017, BioWorld $100M positions Cytokinetics well re Amgen with omecamtiv
February 2, 2017, BioCentury Cytokinetics strikes royalty deal for omecamtiv mecarbil
February 2, 2017, Xconomy Royalty Pharma Pays $90M to Cytokinetics for Heart Drug Royalties
February 2, 2017, BioPharma Dive Cytokinetics pulls in Royalty Pharma to secure $100M
February 2, 2017, First Word Pharma ViewPoints: Cytokinetics, Amgen have long believed omecamtiv mecarbil is a blockbuster in waiting - Royalty Pharma clearly agrees
December 12, 2016, ALS News Today Cytokinetics Presents New Data at 27th International Symposium on ALS/MND
December 5, 2016, Cardiovascular Business Oral heart failure medication proves safe, effective in phase 2 trial
October 13, 2016, Harvard Business School Adding Muscle to the Fight Against Disease

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )